Bioequivalence Study of Lopinavir/Ritonavir 200/50 mg Film Tablet (World Medicine Ilac, Turkey) Under Fasting Conditions
Status:
Completed
Trial end date:
2020-06-11
Target enrollment:
Participant gender:
Summary
A single dose of Reference product containing 200 mg lopinavir and 50 mg ritonavir fixed dose
combination and a single dose of Test product containing 200 mg lopinavir and 50 mg ritonavir
fixed dose combination or vice versa; administered with 240 mL of water at room temperature,
in each period under fasting conditions.
Phase:
Phase 1
Details
Lead Sponsor:
World Medicine ILAC SAN. ve TIC. A.S.
Collaborators:
Farmagen Ar-Ge Biyot. Ltd. Sti Novagenix Bioanalytical Drug R&D Center